Immunomodulation with P40, an insoluble delipidated fraction of Corynebacterium granulosum. II.--Specific immune responses of the host. 1982

P H Lagrange, and M J Fuster

Mice immunized subcutaneously in the footpad with P40, an insoluble fraction extracted from delipidated heat-killed Corynebacterium granulosum, developed systemic mechanisms which depended on the generation of a state of systemic cellular hypersensitivity to P40 antigens. An injection of P40 into the footpad resulted in a striking increase in cell division in the draining lymph node, the development of a state of specific systemic delayed type hypersensitivity and a systemic increase in the bacterial capacity of the host macrophages. The footpad containing the immunizing injection of P40 also reflected the generation and decay of host sensitivity. Whereas the expression of 24-h skin sensitivity reactions to the eliciting injection of P40 antigens peaked at about day 6, the maximal increase of the local granuloma reaction peaked at about day 14, the latter representing a cumulative reaction. These local reactions and systemic hypersensitivity did not develop in congenitally athymic Nude mice. Time- and dose-dependent variations were detected in different strains of mice. Systemic hypersensitivity could be transferred to normal recipients with lymph node cells or spleen cells but not with serum from P40-immunized donors. All the results produced in this report indicate the distinct possibility that the systemic hypersensitivity which developed after P40 sensitization was based on cell-mediated responses to P40 antigens.

UI MeSH Term Description Entries
D006968 Hypersensitivity, Delayed An increased reactivity to specific antigens mediated not by antibodies but by sensitized T CELLS. Hypersensitivity, Tuberculin-Type,Hypersensitivity, Type IV,Tuberculin-Type Hypersensitivity,Type IV Hypersensitivity,Delayed Hypersensitivity,Delayed Hypersensitivities,Hypersensitivity, Tuberculin Type,Tuberculin Type Hypersensitivity,Tuberculin-Type Hypersensitivities,Type IV Hypersensitivities
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D007116 Immunization, Passive Transfer of immunity from immunized to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (ADOPTIVE TRANSFER). Convalescent Plasma Therapy,Immunoglobulin Therapy,Immunotherapy, Passive,Normal Serum Globulin Therapy,Passive Antibody Transfer,Passive Transfer of Immunity,Serotherapy,Passive Immunotherapy,Therapy, Immunoglobulin,Antibody Transfer, Passive,Passive Immunization,Therapy, Convalescent Plasma,Transfer, Passive Antibody
D008198 Lymph Nodes They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system. Lymph Node,Node, Lymph,Nodes, Lymph
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008262 Macrophage Activation The process of altering the morphology and functional activity of macrophages so that they become avidly phagocytic. It is initiated by lymphokines, such as the macrophage activation factor (MAF) and the macrophage migration-inhibitory factor (MMIF), immune complexes, C3b, and various peptides, polysaccharides, and immunologic adjuvants. Activation, Macrophage,Activations, Macrophage,Macrophage Activations
D008297 Male Males
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse

Related Publications

P H Lagrange, and M J Fuster
June 1984, Asian Pacific journal of allergy and immunology,
P H Lagrange, and M J Fuster
January 1984, The Journal of asthma : official journal of the Association for the Care of Asthma,
P H Lagrange, and M J Fuster
July 1981, Comptes rendus des seances de l'Academie des sciences. Serie III, Sciences de la vie,
P H Lagrange, and M J Fuster
January 1977, Developments in biological standardization,
P H Lagrange, and M J Fuster
September 1976, Comptes rendus hebdomadaires des seances de l'Academie des sciences. Serie D: Sciences naturelles,
P H Lagrange, and M J Fuster
June 1984, Veterinary parasitology,
P H Lagrange, and M J Fuster
April 1975, Journal of the National Cancer Institute,
Copied contents to your clipboard!